Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease

View the full release here: https://www.businesswire.com/news/home/20230322005004/en/In addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and Scientific Officer of Medtronic and Helen Liang, Founder & Managing Partner at FoundersX, will join Cognitos Board of Directors. "This funding will accelerate development of Cognitos home-based wearable device which has the potential to be a novel, safe, disease-modifying therapeutic approach to treat neurodegenerative diseases, starting with Alzheimers. His experience as the CMO and CSO of Medtronic, where he was instrumental in building their leading neuroscience medical device business will be extremely helpful to Cognito as we advance our technology for the millions of patients with neurological disorders. ""A non-drug neuromodulation intervention has the potential to better address the complex nature of neurodegenerative diseases such as Alzheimers and Cognito is well-positioned to be a leader in this new paradigm," said Helen Liang, Founder & Managing Partner, FoundersX Ventures. "Cognito is a pioneer at the unique intersection of biology and technology in using neuromodulation to potentially alter the trajectory of neurodegenerative diseases, and were thrilled to support the advancement of this pivotal study in Alzheimers.